Form 4: OptimizeRx Officer Acquires Shares, Covers Taxes

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

Summary

• Marion Odence-Ford, Chief Legal & Admin Officer of OptimizeRx Corp (OPRX), acquired 3,928 shares of common stock on December 19, 2025, through the vesting and conversion of Restricted Stock Units (RSUs).
• The acquisition was at a price of $0 per share, as is typical for RSU conversions.
• Concurrently, 1,153 shares were disposed of at $13.51 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Odence-Ford directly holds 93,373 shares of OptimizeRx common stock.
• An additional 3,928 Restricted Stock Units remain beneficially owned, which are part of a grant vesting in three equal annual installments, with the next installment due on December 19, 2026.

Sentiment

Score: 6

Explanation: The filing reports a routine RSU vesting and tax-related sale, which is a neutral event. The executive's net increase in share ownership is slightly positive, indicating continued alignment with shareholder interests.

Positives

• Marion Odence-Ford increased her net direct ownership of OptimizeRx common stock by 2,775 shares (3,928 acquired 1,153 disposed for tax), indicating continued alignment with shareholder interests.
• The vesting of Restricted Stock Units reflects the company's ongoing executive compensation and retention strategy for a key officer.

Negatives

• A portion of the acquired shares (1,153 shares) was immediately sold to cover tax liabilities, which, while a common practice, reduces the net increase in direct ownership from the RSU vesting.

Future Outlook

NA

Industry Context

This filing reflects routine executive compensation practices within the technology and healthcare sectors, where Restricted Stock Units (RSUs) are a common component of long-term incentive plans designed to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The executive's increased net ownership aligns her interests with shareholders. The tax-related sale is a minor, expected dilution.
• Employees: Reflects standard executive compensation practices, which can be a benchmark for other employees' equity plans.

Next Steps

• The remaining 3,928 Restricted Stock Units are expected to vest on December 19, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine RSU vesting and subsequent tax-related sale by a key executive. Such transactions are standard compensation events and do not provide new fundamental information about the company's operational performance or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

OptimizeRx, OPRX, SEC Form 4, insider trading, beneficial ownership, restricted stock units, RSU vesting, stock acquisition, tax withholding, executive compensation